JP2009521206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521206A5 JP2009521206A5 JP2008508006A JP2008508006A JP2009521206A5 JP 2009521206 A5 JP2009521206 A5 JP 2009521206A5 JP 2008508006 A JP2008508006 A JP 2008508006A JP 2008508006 A JP2008508006 A JP 2008508006A JP 2009521206 A5 JP2009521206 A5 JP 2009521206A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- present
- further embodiment
- receptor alpha
- folate receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 28
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- 238000000034 method Methods 0.000 description 35
- 239000000126 substance Substances 0.000 description 16
- 230000000973 chemotherapeutic effect Effects 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 230000003432 anti-folate effect Effects 0.000 description 10
- 229940127074 antifolate Drugs 0.000 description 10
- 239000004052 folic acid antagonist Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000012642 immune effector Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 102000006815 folate receptor Human genes 0.000 description 4
- 108020005243 folate receptor Proteins 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67418505P | 2005-04-22 | 2005-04-22 | |
| PCT/US2006/016004 WO2006116592A2 (en) | 2005-04-22 | 2006-04-24 | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290406A Division JP2012100675A (ja) | 2005-04-22 | 2011-12-29 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009521206A JP2009521206A (ja) | 2009-06-04 |
| JP2009521206A5 true JP2009521206A5 (https=) | 2011-09-01 |
Family
ID=37215502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508006A Pending JP2009521206A (ja) | 2005-04-22 | 2006-04-24 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| JP2011290406A Pending JP2012100675A (ja) | 2005-04-22 | 2011-12-29 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290406A Pending JP2012100675A (ja) | 2005-04-22 | 2011-12-29 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US20060239910A1 (https=) |
| EP (2) | EP2172487A1 (https=) |
| JP (2) | JP2009521206A (https=) |
| AU (1) | AU2006241099B2 (https=) |
| CA (1) | CA2607444C (https=) |
| WO (1) | WO2006116592A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004249673A1 (en) * | 2003-05-23 | 2004-12-29 | Morphotek, Inc. | Anti alpha - folate - receptor - tetramer antibodies |
| EP1648511A1 (en) * | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| ES2582340T3 (es) * | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| AU2014203172B2 (en) * | 2010-02-24 | 2016-03-10 | Immunogen, Inc. | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof |
| TWI622402B (zh) * | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| CN103347537A (zh) * | 2010-10-20 | 2013-10-09 | 莫弗泰克股份有限公司 | 抗叶酸受体α抗体糖型 |
| MX343607B (es) * | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| CA2830628A1 (en) | 2011-03-18 | 2012-09-27 | Kagoshima University | Composition for treatment and diagnosis of pancreatic cancer |
| BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
| SI2731972T1 (en) | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| US9200073B2 (en) * | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US9207238B2 (en) | 2012-12-07 | 2015-12-08 | Kyowa Hakko Kirin Co., Ltd. | Anti-FOLR1 antibody |
| CA2914237A1 (en) | 2013-06-20 | 2014-12-24 | Morphotek, Inc. | Methods for treatment of ovarian cancer |
| CN113150145B (zh) | 2013-08-30 | 2025-02-14 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| EP4141032B1 (en) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| EP3283886B1 (en) * | 2015-04-17 | 2020-01-15 | Eisai Inc. | Methods for treating lung cancer |
| CN116440279B (zh) | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| WO2017053423A1 (en) | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| AU2019236091B2 (en) | 2018-03-13 | 2025-06-05 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
| KR102275930B1 (ko) | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7426661B2 (ja) * | 2018-12-17 | 2024-02-02 | 株式会社カネカ | 特定抗原特異的抗体を産生する細胞のスクリーニング方法 |
| MA55818A (fr) | 2019-04-29 | 2022-03-16 | Immunogen Inc | Anticorps et immunoconjugués de fr-alpha biparatopique |
| WO2024104431A1 (zh) * | 2022-11-16 | 2024-05-23 | 迈威(上海)生物科技股份有限公司 | 一种靶向FRα的抗体或其抗原结合片段及其应用 |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| US12378314B1 (en) | 2024-02-02 | 2025-08-05 | Medicovestor, Inc. | Proteins that bind folate receptor alpha including fully-human antibodies |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) * | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5006470A (en) * | 1987-04-16 | 1991-04-09 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cell surface antigens of melanoma |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992007081A2 (en) | 1990-10-12 | 1992-04-30 | THE UNITED STATES OF AMERICA as represented by TH E SECRETARY, U.S. DEPARTMENT OF COMMERCE | A monoclonal antibody |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US6191268B1 (en) * | 1993-12-17 | 2001-02-20 | Dana-Farber Cancer Institute | Compositions and methods relating to DNA mismatch repair genes |
| CA2182206A1 (en) * | 1994-01-27 | 1995-08-03 | William A. Haseltine | Human dna mismatch repair proteins |
| DE19513676A1 (de) * | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| ATE254931T1 (de) * | 1996-01-05 | 2003-12-15 | Us Gov Health & Human Serv | Mesothelinantigen, verfahren und testsatz zur targetierung |
| AU719513B2 (en) | 1996-05-04 | 2000-05-11 | Astrazeneca Ab | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6146894A (en) | 1998-04-14 | 2000-11-14 | The Johns Hopkins University | Method for generating hypermutable organisms |
| US6365410B1 (en) * | 1999-05-19 | 2002-04-02 | Genencor International, Inc. | Directed evolution of microorganisms |
| EP2011801A1 (en) * | 1999-05-27 | 2009-01-07 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| US6808894B1 (en) * | 2000-11-07 | 2004-10-26 | Morphotek, Inc. | Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics |
| EP1345495B1 (en) | 2000-11-07 | 2009-02-25 | Morphotek Inc. | Methods for generating genetically altered antibody-producing cell lines with improved antibody characteristics |
| WO2002054856A1 (en) | 2001-01-15 | 2002-07-18 | Morphotek Inc. | Chemical inhibitors of mismatch repair |
| CN101979095A (zh) * | 2001-05-02 | 2011-02-23 | 普渡研究基金会 | 巨噬细胞介导的疾病的治疗和诊断 |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| AR036154A1 (es) | 2001-05-18 | 2004-08-18 | Boehringer Ingelheim Pharma | Anticuerpos especificos de cd44v6. |
| CA2481334A1 (en) | 2002-04-01 | 2003-10-16 | Anthony C. Stevens | Tissue-specific endothelial membrane proteins |
| WO2004009782A2 (en) | 2002-07-19 | 2004-01-29 | Morphotek, Inc. | Methods for generating enhanced antibody-producing cell lines with improved growth characteristics |
| AU2004249673A1 (en) * | 2003-05-23 | 2004-12-29 | Morphotek, Inc. | Anti alpha - folate - receptor - tetramer antibodies |
| EP1648511A1 (en) | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| WO2005014652A1 (en) | 2003-08-05 | 2005-02-17 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
| EP3101034A1 (en) * | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| AU2005294131A1 (en) | 2004-10-05 | 2006-04-20 | Wyeth | Methods and compositions for improving recombinant protein production |
| EP1861425B1 (en) * | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| ATE460668T1 (de) * | 2005-03-30 | 2010-03-15 | Purdue Research Foundation | Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren |
| CA2607444C (en) * | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| US8795633B2 (en) * | 2005-09-23 | 2014-08-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
| US20080312093A1 (en) * | 2005-11-04 | 2008-12-18 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
| EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| JP2010509570A (ja) * | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| US20090087849A1 (en) * | 2007-09-06 | 2009-04-02 | Tripath Imaging, Inc. | Nucleic acid-based methods and compositions for the detection of ovarian cancer |
| GB0725077D0 (en) | 2007-12-21 | 2008-01-30 | Univ Murcia | Antifolate com[ounds for the treatment of melanoma |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| CN103347537A (zh) * | 2010-10-20 | 2013-10-09 | 莫弗泰克股份有限公司 | 抗叶酸受体α抗体糖型 |
| MX343607B (es) * | 2010-11-05 | 2016-11-11 | Morphotek Inc | Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. |
| BR112014028306A2 (pt) * | 2012-05-15 | 2018-04-17 | Morphotek, Inc. | métodos para tratamento de câncer gástrico. |
| US9207238B2 (en) * | 2012-12-07 | 2015-12-08 | Kyowa Hakko Kirin Co., Ltd. | Anti-FOLR1 antibody |
| CA2914237A1 (en) * | 2013-06-20 | 2014-12-24 | Morphotek, Inc. | Methods for treatment of ovarian cancer |
| EP3283886B1 (en) * | 2015-04-17 | 2020-01-15 | Eisai Inc. | Methods for treating lung cancer |
| PE20231050A1 (es) * | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
-
2006
- 2006-04-24 CA CA2607444A patent/CA2607444C/en not_active Expired - Lifetime
- 2006-04-24 EP EP20090176155 patent/EP2172487A1/en not_active Withdrawn
- 2006-04-24 EP EP06758662A patent/EP1879922A2/en not_active Withdrawn
- 2006-04-24 US US11/410,442 patent/US20060239910A1/en not_active Abandoned
- 2006-04-24 JP JP2008508006A patent/JP2009521206A/ja active Pending
- 2006-04-24 WO PCT/US2006/016004 patent/WO2006116592A2/en not_active Ceased
- 2006-04-24 AU AU2006241099A patent/AU2006241099B2/en not_active Expired
-
2009
- 2009-07-16 US US12/503,983 patent/US8124083B2/en active Active
-
2011
- 2011-12-29 JP JP2011290406A patent/JP2012100675A/ja active Pending
-
2012
- 2012-01-24 US US13/356,724 patent/US9144614B2/en active Active
-
2015
- 2015-07-27 US US14/809,887 patent/US9522195B2/en not_active Expired - Lifetime
-
2016
- 2016-11-08 US US15/346,332 patent/US10253106B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521206A5 (https=) | ||
| JP2012100675A5 (https=) | ||
| US20250376540A1 (en) | Binding Proteins 1 | |
| AU2018250312C1 (en) | Bioorthogonal compositions | |
| ES2719495T5 (en) | Anti-b7-h6 antibody, fusion proteins, and methods of using the same | |
| EP2513146B1 (en) | Antibodies against ror1 capable of inducing cell death of cll | |
| KR102414718B1 (ko) | 암의 진단 및 치료를 위한 조성물 및 방법 | |
| JP2016509582A5 (https=) | ||
| EP3448987A2 (en) | Compositions for the treatment of disease | |
| CA2925915C (en) | Anti-epcam antibodies and methods of use | |
| JP2012100676A5 (https=) | ||
| JP2012100677A5 (https=) | ||
| JP2012521217A5 (https=) | ||
| JP2013518912A5 (https=) | ||
| KR20160006697A (ko) | 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법 | |
| US11666664B2 (en) | Self assembling molecules for targeted drug delivery | |
| JP2022513421A5 (https=) | ||
| JP2014500862A5 (https=) | ||
| JP6814824B2 (ja) | アポトーシスを誘導するための組成物及び方法 | |
| JP2014515600A5 (https=) | ||
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| CN115279789A (zh) | 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法 | |
| CA3231445A1 (en) | B7-h3 targeting fusion proteins and methods of use thereof | |
| KR20140090295A (ko) | T 세포 특이적인 인간화 단일조각항체 전달체 | |
| US20230065416A1 (en) | Clathrin-chimetic antibody receptor constructs for immune cell activation therapy in vivo |